Widely-anticipated trial results for three neuroprotective drugs in secondary progressive multiple sclerosis have been disappointingly negative, researchers told the ECTRIMS meeting in Berlin. Presented at the 34th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) on 12 October, the findings from the MS-SMART trial of amiloride, riluzole and fluoxetine showed no effect ...
ECTRIMS: 3 neuroprotective drugs have no effect in progressive MS
By Michael Woodhead
17 Oct 2018